Buloxibutid

DRUG2 trials

Sponsors

Vicore Pharma AB

Conditions

Idiopathic Pulmonary Fibrosis (IPF)idiopathic pulmonary fibrosis

Phase 2

A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Active, not recruitingNCT06588686

Vicore Pharma ABIdiopathic Pulmonary Fibrosis (IPF)

Start: 2024-12-09End: 2027-06-01Updated: 2026-08-17

A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial evaluating the efficacy and safety of 2 doses of buloxibutid over 52 weeks in people with idiopathic pulmonary fibrosis.

RecruitingCTIS2023-509069-19-00

Vicore Pharma ABidiopathic pulmonary fibrosis

Start: 2024-12-12Target: 90Updated: 2026-01-25

Related Papers

ASPIRE Trial in Idiopathic Pulmonary Fibrosis: A Patient Experience-focused Phase 2b Randomized, Double-blind, Placebo-controlled, Multicenter Trial of the Novel Angiotensin II Type 2 Receptor Agonist Buloxibutid

American Journal of Respiratory and Critical Care Medicine2025-05-01